Abstract: Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L?, NT71, NT72, NT73, NT74, NT75, NT76, or NT77.

Abstract: Pharmaceutical compositions for buccal delivery of zolpidem comprising an effective amount of zolpidem and a carbonate and bicarbonate buffer system in an amount sufficient to raise the pH of saliva to at least 8.5, and wherein the carbonate forms a coating on the bicarbonate wherein the amount of carbonate coating is at least 30% (w/w) of the total buffer amount are described. Pharmaceutical compositions for buccal delivery of zolpidem comprising an effective amount of zolpidem and a binary buffer system of carbonate and bicarbonate, wherein the carbonate and bicarbonate are co-located in a single particle, wherein the bicarbonate is coated with the carbonate, and wherein the amount of carbonate coating is at least 30% (w/w) of the binary buffer system are also described.

Abstract: Pharmaceutical compositions for buccal delivery of zolpidem comprising an effective amount of zolpidem and a carbonate and bicarbonate buffer system in an amount sufficient to raise the pH of saliva to at least 8.5 irrespective of starting pH, and wherein the carbonate forms a coating on the bicarbonate wherein the amount of carbonate coating is at least 30% (w/w) of the total buffer amount are described. Methods of treating insomnia in a subject are described, the method including the step of administering to the subject the pharmaceutical composition of the present invention, wherein the administering is on an as-needed basis. Method of treating MOTN insomnia in a subject are also described.

Abstract: The present invention relates to pharmaceutical compositions useful for the treatment of subjects suffering from an infection or disease caused by herpes virus strains that are resistant to treatment with acyclovir. In particular, it has been discovered that the low dosage amounts of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU) are effective in inhibiting replication of acyclovir-resistant HSV strains. The present invention is also directed to methods of the preparation of pharmaceutical antiviral compositions and to the methods of their use in the treatment of infection or disease.

Abstract: The present invention relates to pharmaceutical compositions useful for the treatment of subjects suffering from an infection or disease caused by the hepatitis B virus (HBV). In particular, it has been discovered that the administration of low dosage amounts of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU) to humans chronically infected with HBV is effective to reduce drastically circulating markers associated with HBV. The present invention is also directed to methods of the preparation of pharmaceutical antiviral compositions.

Abstract: A kit for use in the visualization of genital warts or other atypical epithelia is disclosed. The kit provides a standardized quantity of acetic acid solution on readily available disposable towelettes sealed in a tear-open pouch for use in colposcopy. Methods for visualizing genital warts utilizing the kit are also disclosed.